International Journal of Medical Laboratory Research (IJMLR)

THE HEMATOLOGICAL CHANGES ASSOCIATED WITH COVID-19 VACCINE AMONG PEOPLE SEEKING VACCINATION AT THIKA LEVEL 5 HOSPITAL, KIAMBU COUNTY, KENYA

​

Joyce Gachoki, Caroline Ngugi, Stanley Waithaka, Cleophas Kyama 

​

Abstract: Vaccination still remains the cornerstone of protection against SARS CoV2.S to date. Data has shown that the vaccine starts working soon after the first dose and has an efficacy rate of 95% seven days after the second dose. This means that about 95% of people who get the vaccine are protected from becoming seriously ill. The objective was to determine the hematological changes associated with the COVID-19 vaccine among the general population. A blood sample was drawn from the subjects before vaccination and analyzed for coagulation profile (D-dimer) and full blood count profile. The same analysis was done just before the administration of the second dose and six months after the second dose using BC 5000 Automated Hematology Analyzer and C3510 Auto coagulation analyzer respectively. Data was entered in excel sheets and exported to SPSS version 29 of 2023 analysis software program for statistical analysis. Of the 100 samples, 56 (56%) were male and 44 (44%) females with their age being between 20-75years and a mean age group of 25-35 years. Of these only 2 (2%) had a confirmed covid-19 test previously with the rest 98 (98%) having had not been tested for covid-19. Of the total subjects 10 (10%) had blood pressure, 6(6%) had diabetes and the rest 84 (84%) had no underlying conditions. There was no statistically significant difference between the change in the, hemoglobin, white blood cells, d-dimer levels with all having a p-value <0.05. From the study we conclude that the covid-19 vaccine is safe for administration but close monitoring of the vaccinated individuals is necessary.

KEYWORDS: SARS CoV2-19, Vaccine, Immunity

​

REFERENCES:​

1. [1]. FDA. FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine. FDA News Release [Internet]. 2021;(December).

2. [2]. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- research that is available on the COVID-19 resource centre - including this for unrestricted research re-use a. 2020;(January):19–21.

3. [3]. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol [Internet]. 2021;21(8):475–84. Available from: https://doi.org/10.1038/s41577-021-00578-z

4. [4]. Ministry of Health. COVID-19 Weekly Epidemiological Update. World Heal Organ. 2021;(February):1–33.

5. [5]. Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, et al. SARS-CoV-2 Variants, Vaccines, and Host Immunity. Front Immunol. 2022;12(January):1–21.

6. [6]. Vanaparthy R, Mohan G, Vasireddy D, Atluri P. Review of covid-19 viral vector-based vaccines and covid-19 variants. Infez Med. 2021;29(3):328– Table 5; Pairwise comparisons for hematological and coagulation parameters 38.

7. [7]. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol . 2021;21(8):475–84.

8. [8]. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92.

9. [9]. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15.

10. [10]. Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem. 2021;36(4):427–39.

11. [11]. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol [Internet]. 2021;21(2):83–100.

12. [12]. Jain U. Effect of COVID-19 on the Organs. Cureus. 2020;12(8):1–8.

13. [13]. Al-Saadi EAKD, Abdulnabi MA. Hematological changes associated with COVID-19 infection. J Clin Lab Anal. 2022;36(1):1–12.

14. [14]. Elderdery AY, Elkhalifa AME, Alsrhani A, Zawbaee KI, Alsurayea SM, Escandarani FK, et al. Complete Blood Count Alterations of COVID-19 Patients in Riyadh, Kingdom of Saudi Arabia. J Nanomater. 2022;2022.

15. [15]. Araya S, Mamo MA, Tsegay YG, Atlaw A, Aytenew A, Hordofa A, et al. Blood coagulation parameter abnormalities in hospitalized patients with confirmed COVID-19 in Ethiopia. PLoS One. 2021;16(6 June):1–9.

16. [16]. Mouhat B, Besutti M, Bouiller K, Grillet F, Monnin C, Ecarnot F, et al. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients. Eur Respir J. 2020;56(4):1–11.

17. [17]. Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. Mol Ther. 2019;27(4):710–28.

18. [18]. Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, Da Silva J, et al. Morbidity and Mortality Weekly Report Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19-Georgia, March 2020. US Dep Heal Hum Serv. 2020;69(18):545–50.

19. [19]. Ogston SA, Lemeshow S, Hosmer DW, Klar J, Lwanga SK. Adequacy of Sample Size in Health Studies. Biometrics. 1991;47(1):347.

20. [20]. Palladino M. Complete blood count alterations in covid-19 patients: A narrative review. Biochem Medica. 2021;31(3):1–13.

21. [21]. WHO. Update on COVID-19 vaccines & immune response Current global situation. 2020;(February):1–19. Covid-19 Vaccine. 2024;(March):2024.

22. [22]. Pilishvili T, Fleming-Dutra KE, Farrar JL, Gierke R, Mohr NM, Talan DA, et al. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021. MMWR Recomm Reports. 2021;70(20):753–8.